Policy Watch
Refine Results
- view as grid
- view as list
Mixed Prospects for Vaccinating Children
In this Axios column, Drew Altman examines the data about what parents say they will do once their children ages 5-11 become eligible for a COVID-19 vaccine, and why it will take some time and a concerted outreach effort to match adult vaccination rates.
Perspective Read MoreA Look at Who is Still Not Vaccinated Against COVID
In this Axios column, Drew Altman takes on the idea that communities of color are behind the problem of the unvaccinated in the U.S.
Perspective Read MoreWhy The California Recall Is Not a Harbinger of What Is to Come on COVID As a Campaign Issue
In this Axios column, Drew Altman examines the lessons for COVID-19 as a political issue from Governor Gavin Newsom’s resounding win in California’s recall election.
Perspective Read MoreParents Report More Negative Pandemic Effects on Kids Who Attend School Virtually vs. In-Person
In his latest Axios column, Drew Altman shows that parents feel that children have fared better during COVID attending school in-person than virtually in terms of academic performance and their mental health and wellbeing.
Perspective Read MoreHow Full FDA Approval Could Spur Vaccination
In this Axios column, Drew Altman says full FDA approval of COVID-19 vaccines can provide a big boost to vaccination efforts if treated as an opportunity for updated messaging from government officials at all levels and public health experts and new actions from employers.
Perspective Read MoreThe Health System Appears To Be Selling LGBT+ People Short
With much focus on equity in the nation’s health care system during the pandemic, Drew Altman’s Axios column brings attention to warning signs about health care provided to LGBT+ individuals.
Perspective Read MoreThe Sleeper Health Cost Policy
In this Axios column, Drew Altman unpacks President Biden’s recent executive order on promoting competition, exploring its significance for new efforts to control health costs by addressing consolidation in the health care industry.
Perspective Read MoreWhy Drug Price Negotiation Has Staying Power
In this Axios column, Drew Altman looks beyond Medicare to what’s at stake for employers and workers in the debate about the government negotiating drug prices.
Perspective Read MorePersistent Vaccine Myths
With news that the country has now vaccinated half of its population with at least one dose, This Drew Altman Axios column highlights the persistent COVID-19 vaccine myths that are believed by a substantial portion of the unvaccinated population and discusses the options to address vaccine misinformation.
Perspective Read MoreWe aren’t getting a national vaccine ‘passport.’ So let’s use the next best thing: CDC vaccination cards.
In this op-ed for The Washington Post, Drew Altman suggests a way out of the heated debate about a COVID-19 vaccination passport to help provide clarity about who is vaccinated and who still ought to wear masks in public spaces or the workplace by using something that already exists– CDC vaccination cards.
Perspective Read More